Tumori最新文献

{"title":"Volunteering in a pediatric oncology unit: Motivations and duration.","authors":"Maura Massimino, Paolo Grampa, Luca Pellizzer, Stefania Majno, Francesca Bartolini, Cora Querzè, Andrea Pellegrini, Andrea Giacobetti, Immacolata Di Carlo, Natale Antonio Finocchio, Nadia Rossin, Francesca Viganò, Raffaele Bianchi, Lucia Contro, Daniela Bisotti, Matteo Silva, Andrea Ferrari, Carlo Alfredo Clerici, Francesco Barretta","doi":"10.1177/03008916251404296","DOIUrl":"10.1177/03008916251404296","url":null,"abstract":"<p><strong>Background: </strong>Volunteers play an essential role in pediatric oncology. While they are driven by personal motivations, they usually receive specific training that may support or reshape their goals.</p><p><strong>Methods: </strong>We conducted a questionnaire-based survey to assess demographics, motivations, and satisfaction among eight associations/non-profit organizations, representing approximately 120 volunteers. The objectives were to explore the nature and correlations of their motivations to evaluate the sustainability of their engagement.</p><p><strong>Results: </strong>Sixty-nine volunteers completed the questionnaire, either in full or in part. Most respondents were women, with a median age of 59 years, a medium-to-high educational level, and more than five years of experience in volunteering. Their commitment was mainly driven by personal/family experiences with childhood cancer. They demonstrated a strong awareness of cancer-related issues and were motivated by the desire to improve the quality and innovation of care. Participation within associations fostered a sense of community and altruistic purposes. High levels of satisfaction often led them to encourage others to volunteer. Previous rewards or recognition were not considered a major motivating factor.</p><p><strong>Conclusions: </strong>Effective volunteer engagement and retention depend on a clear understanding of volunteers' expectations and on the selective recruitment of individuals whose goals align with the organization's capacity to meet them.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"32-39"},"PeriodicalIF":2.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146011862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LDCT-based lung cancer screening and small cell lung cancer: Limited but non-negligible impact on survival. A brief report.","authors":"Roberta Eufrasia Ledda, Federica Sabia, Camilla Valsecchi, Luigi Rolli, Margherita Ruggirello, Alfonso Vittorio Marchianò, Ugo Pastorino","doi":"10.1177/03008916251392738","DOIUrl":"10.1177/03008916251392738","url":null,"abstract":"<p><p>Low-dose computed tomography (LDCT)-based lung cancer screening (LCS) seems to have very limited impact on small cell lung cancer (SCLC) outcomes. This study aims at describing frequency and outcomes of SCLC in a large LCS population.Patients diagnosed with SCLC among the total population enrolled in three different trials (n = 7473) were selected for the present analysis. Demographic and clinical data were collected at the baseline and follow-up screening rounds, while the vital status and date of death were obtained through a dedicated national platform. Of the 396 diagnosed LCs, 28 (7.1%) were SCLCs; median survival time from the diagnosis was 1.5 years, and overall mortality was 71.4%. Screen-detected SCLCs were 20/28 (71.4%); 5/20 (25%) were prevalent cancers and 15/20 (75%) incident ones. Five-year mortality among the screen-detected and non-screen detected SCLCs was 70% and 62.5%, respectively.The frequency of SCLC was lower as compared to other trials. Although no significant differences in five-year mortality were observed between screen-detected and non-screen-detected SCLCs, the overall five-year mortality was substantially lower than that reported in non-LCS populations, suggesting that LDCT-based LCS has an impact on SCLC outcome, albeit limited.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"83-86"},"PeriodicalIF":2.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12916859/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145769288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expectant management or conization for persistent low-grade cervical intraepithelial neoplasia: Analysis of 5-year outcomes.","authors":"Giorgio Bogani, Francesco Sopracordevole, Giovanni Corso, Enrico Vizza, Paolo Scollo, Andrea Giannini, Violante Di Donato, Andrea Ciavattini, Rosa De Vincenzo, Barbara Gardella, Flavia Sorbi, Massimiliano Fambrini, Fabio Ghezzi, Jvan Casarin, Marco Petrillo, Caterina Borso, Noemi Tonti, Valentina Chiappa, Francesco Raspagliesi, Giuseppe Vizzielli","doi":"10.1177/03008916251395597","DOIUrl":"10.1177/03008916251395597","url":null,"abstract":"<p><strong>Objective: </strong>To investigate to describe outcomes of conization or expectant management for women with persistent (>24 months) low-grade cervical intra-epithelial neoplasia.</p><p><strong>Methods: </strong>This is a retrospective analysis focusing on five-year outcomes after persistent, histologically confirmed, low-grade cervical intra-epithelial neoplasia undergoing conization or expectant management.</p><p><strong>Results: </strong>Charts of 219 women with persistent low-grade cervical lesions were retrieved. Overall, 98 (44.7%) and 121 (55.3%) women had conization and observation, respectively. Patients receiving conization were older than patients having observation (43 (range, 24-77) vs. 39 (range, 25-68) years; p=0.013). Focusing on the group of patients receiving conization, 16 (16.3%) women were diagnosed with CIN2+. The five-year risk of secondary conization was 5% (n=5). Focusing on patients having observation (n=121), 18 (14.8%) patients received conization, after a median of 16.5 (range, 6-30) months. Seven (5.8%) and 11 (9.1%) patients were diagnosed with persistent CIN1 and CIN2+, respectively. Not fully visible squamous-columnar junction at colposcopic examination (p=0.035) was associated with CIN2+ occurrence. No invasive cancer was observedConclusions:Conization for persistent low-grade cervical intra-epithelial neoplasia revealed \"occult\" CIN2+ in 16% of patients. However, expectant management appears safe and effective in this context, in women with fully visible squamous columnar junction. The decision between conization and expectant management should be discussed on an individual basis.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"75-82"},"PeriodicalIF":2.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146011683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in histological subtypes of cutaneous melanoma in the Netherlands from 1989 to 2023 - Influence of sunlight exposure and overdiagnosis.","authors":"Catharina C van Niekerk, André L M Verbeek, Erik Brummelkamp, J Hans D M Otten, J Hans M M Groenewoud, Michelle M van Rossum, Jessie J J Gommers","doi":"10.1177/03008916251388862","DOIUrl":"10.1177/03008916251388862","url":null,"abstract":"<p><strong>Introduction: </strong>Melanoma incidence has continued to increase over the past decades with unchanged mortality. Different sunshine exposures across the generations complicate the interpretation of the trends. It is further suggested that half of the rising incidence rate is caused by overdiagnosis. We compared the time trends in the major but not all sunlight-related histological subtypes of cutaneous melanoma in the Netherlands in 1989-2023.</p><p><strong>Methods: </strong>With data from the Netherlands Cancer Registry, trends were assessed for superficial spreading melanoma (SSM, n=93,067), lentigo maligna melanoma (LMM, n=26,237), and nodular melanoma (NM, n=15,658). Numbers and rates were analysed by age, calendar period, and birth cohort for people born in 1925-1985. To study significant changes across the years, the joinpoint regression model was used. For the projection of new cases to 2043, we applied the Nordpred method.</p><p><strong>Results: </strong>During the past 25 years, age-standardised incidence rates for melanoma in situ increased ninefold, for invasive melanoma threefold. Significant rises were noted for SSM and LMM (fourfold) and NM (twofold). The successively born cohorts showed consistent increases in incidence rate for SSM and LMM, but to a lesser degree for NM. Around 2030, the incidence rates for all types of melanomas are expected to be highest, at approximately 100 per 100,000 population.</p><p><strong>Conclusions: </strong>The incidence of melanoma showed a steady increase from 1989 onwards. This was before early detection (that may cause overdiagnosis), was put into clinical practice. Birth cohort analysis of trends in histological subtypes will further contribute to the quantification of overdiagnosis.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"51-58"},"PeriodicalIF":2.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12916882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145998914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medical decision analysis for personalized oncology at the patient bedside.","authors":"Paolo G Casali, Lisa Licitra, Salvatore Provenzano, Ilaria Pellegrini, Chiara Fabbroni, Andrea Franza, Claudia Giani, Dario Callegaro, Stefano Cavalieri, Francesco Lanza, Anna Maria Frezza, Bruno Vincenzi, Renato Muzzini, Annalisa Trama, Rosalba Miceli, Gabriele Tinè, Valter Torri, Virginia Sanchini, Hykel Hosni, Paolo Bruzzi","doi":"10.1177/03008916251404283","DOIUrl":"10.1177/03008916251404283","url":null,"abstract":"<p><p>Medical decision analysis is a method to make rational clinical decisions under uncertainty, enabling a mathematical combination of <i>probabilities</i> and <i>utilities</i> (i.e. values assigned to outcomes under risk). Decision analysis is commonly used in health economics, but it is underexploited in the clinic. With a view to fostering the use of medical decision analysis at the cancer patient bedside, this paper provides basic templates for some typical clinical decisions in cancer treatment, namely affecting: the quantity/quality of life trade-offs in curable cancer; adjuvant/neoadjuvant treatments; cytoreductive treatments; active surveillance / watchful waiting choices; treatment of advanced cancer; cancer follow-up. The clinical use of medical decision analysis is challenged by several difficulties, which are briefly recalled. Contrary to clinical research, medical decision analysis does not build new evidence: it simply provides physicians with a method to personalize clinical decisions on the basis of available evidence. Its added value in clinical practice correlates with the complexity of a decision. However, it also has a great potential in medical education, in order to empower clinicians with skills improving their ability to rationally shape medical decisions and share them properly with their patients.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"11-21"},"PeriodicalIF":2.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12916885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146041767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letrozole for hormone receptor-positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trial.","authors":"Alessio Carbone, Elena Biagioli, Vanda Salutari, Domenica Lorusso, Nicoletta Provinciali, Luca Bocciolone, Grazia Artioli, Chiara Abeni, Nicoletta Colombo, Ugo De Giorgi, Valentina Guarneri, Chiara Cassani, Giovanna Scarfone, Laura Zavallone, Nicoletta Donadello, Violante Di Donato, Monica Giordano, Elvira Scelzi, Germana Tognon, Maria Cristina Petrella, Maurizio D'Incalci, Sergio Marchini, Hoai Thu Dang, Maria Francesca Alvisi, Davide Corradengo, Tania Buttiron Webber, Laura Paleari, Irene Maria Briata, Mariangela Rutigliani, Martino Oliva, Eliana Rulli, Andrea DeCensi","doi":"10.1177/03008916251395596","DOIUrl":"10.1177/03008916251395596","url":null,"abstract":"<p><strong>Background: </strong>Epidemiological and retrospective studies suggest that letrozole may improve outcomes in low-grade serous carcinoma of the ovary (LGSCO) by targeting estrogen-driven tumor progression.</p><p><strong>Methods: </strong>We designed a multicenter, randomized, open-label, phase III trial to compare letrozole versus standard chemotherapy (carboplatin plus paclitaxel) in prolonging progression-free survival (PFS). Secondary endpoints include overall survival (OS), objective response rate (ORR), quality of life (MENQoL), and musculoskeletal pain (BPI-SF). Translational objectives explore mutational and expression profiles (NGS, RAD51/BRCA1 foci) and circulating tumor DNA (ctDNA) as markers of treatment response. Eligible patients are postmenopausal women with stage III-IV ER/PgR-positive LGSCO after primary cytoreductive surgery. Patients are randomized 1:1 to letrozole 2.5 mg daily until progression or unacceptable toxicity, or to carboplatin-paclitaxel for 6-8 cycles. Disease progression is assessed by RECIST, CA-125, and imaging every 3-6 months.</p><p><strong>Results: </strong>As of March 2025, 46 patients have been randomized (23 per arm). Preliminary analysis shows a favorable safety profile for letrozole compared with chemotherapy.</p><p><strong>Conclusions: </strong>Early findings suggest letrozole is well tolerated and may represent a viable therapeutic option for hormone receptor-positive LGSCO. Ongoing molecular and clinical analyses will clarify its role in this rare subtype.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT05601700; https://clinicaltrials.gov/study/NCT05601700.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"67-74"},"PeriodicalIF":3.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145757895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Generative AI and medical oncologists: Be curious, but cautious!","authors":"Silvana Quaglini, Lucia Sacchi, Federico Sottotetti, Andrea Premoli, Laura D Locati","doi":"10.1177/03008916251388549","DOIUrl":"10.1177/03008916251388549","url":null,"abstract":"<p><p>The purpose of this editorial is to explore the potential and risks of using AI in the medical field, particularly in oncology. We describe the history of AI from its origins to the present day, highlighting its positive aspects and potential for each type of AI (expert system, machine learning, generative AI). Technologies like ChatGPT are increasingly being used across various domains; however, without proper caution, they can give rise to phenomena such as 'AI hallucinations'-responses that may appear precise, detailed, clear, and logical, but are in fact entirely fabricated and unfounded, potentially confusing those who read them. We want to caution oncologists against the unconditional use of these technologies, where human input remains still essential both in interpreting the responses and in formulating the questions.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"6-10"},"PeriodicalIF":2.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12916869/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145935346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switching.","authors":"Mariangela Gaudio, Anna Floreani, Greta Schivardi, Domiziana Alaimo, Vera Basilico, Isabella Lorenzetti, Cristina Crepaldi, Benedetta Tinterri, Antonella Panzardi, Daniela Strada, Giuseppe Saltalamacchia, Flavia Jacobs, Chiara Benvenuti, Riccardo Gerosa, Jacopo Canzian, Giovambattista Rodà, Nicla La Verde, Rebecca Pedersini, Fabio Conforti, Gianpiero Rizzo, Rosalba Torrisi, Armando Santoro, Paolo Angelo Cortesi, Rita De Sanctis, Alberto Zambelli","doi":"10.1177/03008916251401048","DOIUrl":"10.1177/03008916251401048","url":null,"abstract":"<p><p>PurposePatients with HER2+ breast cancer (BC) can receive pertuzumab/trastuzumab (PT) subcutaneous (SC) or intravenous (IV) with similar efficacy. This study explores patients and healthcare professionals (HCPs) perceptions post-PT-SC implementation, alongside a pharmacoeconomic analysis.MethodsThis multicentre observational study included semi-structured interviews with HER2+ BC patients (SC or IV) and HCPs from six Lombardy (Italy) BC units plus a pharmacoeconomic analysis of organisational and cost impact. Data were analysed using descriptive statistics and thematic analysis to identify key themes: safety perception, treatment comfort, and trust issues.ResultsAmong 102 patients, 10.8% received only IV, 12.7% only SC, and 76% both; 3.8% of SC patients discontinued due to side effects. Trust scores were high for oncologists and nurses, positively influencing switching. SC was perceived as quicker (81.4%), less invasive (69.8%) and timesaving (71.2%), with over half (56.9%) perceiving equal safety. Among patients exposed to both, 90.7% preferred SC due to lower invasiveness. SC was perceived to be associated with fewer gastrointestinal side effects but more local reactions. IV-preferring patients cited fear of side effects, reduced efficacy, and lack of HCP recommendation. Most HCPs rated SC as faster and workflow-improving; observation and error risk were not major barriers. Non-drug costs were 63% lower with SC, while total treatment costs were comparable (+1.9%).ConclusionBoth patients and HCPs showed high acceptance of PT-SC, offering clear benefits in time, cost, and workflow efficiency. High trust in oncologists and nurses supported its adoption. Time savings may enhance hospital efficiency and patient experience.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"22-31"},"PeriodicalIF":3.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145757916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nutritional status as a risk factor for adverse events associated with L-Asparaginase in children with acute lymphoblastic leukemia.","authors":"Jesús Alonso Gándara-Mireles, Verónica Loera Castañeda, Ismael Lares-Assef, Elio Aarón Reyes Espinoza, Lourdes Patricia Córdova Hurtado, Julio Cesar Grijalva Ávila, Ignacio Villanueva Fierro, Leslie Patrón Romero, Horacio Almanza Reyes","doi":"10.1177/03008916251404280","DOIUrl":"10.1177/03008916251404280","url":null,"abstract":"<p><strong>Background: </strong>Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, and asparaginase (ASNase) is a key component of its treatment. However, ASNase is frequently associated with adverse events (AEs), such as pancreatitis and hypersensitivity reactions particularly with the <i>Escherichia coli</i> derived formulation (L-Asp) which may be influenced by nutritional status.</p><p><strong>Objective: </strong>To evaluate the association between protein-energy malnutrition (PEM) and the incidence of L-Asp induced AEs in children with ALL.</p><p><strong>Methods: </strong>A prospective observational cohort with a nested case-control comparative analysis was conducted in 91 pediatric patients treated with L-Asp. Anthropometric measurements, anti-L-Asp antibody detection, and AEs occurrence were assessed.</p><p><strong>Results: </strong>Eighteen patients (19.8%) developed AEs: six pancreatitis and 12 hypersensitivity reactions. Of these, 14 (77.7%) had PEM. PEM was significantly associated with AEs (OR = 12.22; p = 0.02). Pancreatitis occurred mostly during induction and affected 83.3% of PEM patients. Hypersensitivity reactions were more frequent during reinduction and were associated with anti-L-Asp antibodies in all cases, 75% of which had PEM.</p><p><strong>Conclusions: </strong>PEM was significantly linked to increased risk of L-Asp related toxicity, suggesting nutritional status as a modifiable factor. Early identification and correction of PEM may improve the safety profile of L-Asp in pediatric ALL therapy.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"40-50"},"PeriodicalIF":2.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145990849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abdominal specimen retrieval in endometrial cancer patients with large uteri.","authors":"Simone Bruni, Francesco Raspagliesi, Enrico Vizza, Francesco Fanfani, Jvan Casarin, Fabio Ghezzi, Lorenzo Ceppi, Luca Sorrentino, Valentina Chiappa, Carlotta Caia, Andrea Giannini, Violante Di Donato, Stefano Restaino, Giuseppe Vizzielli, Giorgio Bogani","doi":"10.1177/03008916251389485","DOIUrl":"10.1177/03008916251389485","url":null,"abstract":"<p><strong>Objective: </strong>Endometrial cancer surgery has a low risk of specimen fragmentation, but removing large uteri can be challenging. This study aimed to assess whether the use of minilaparotomic incision for specimen retrieval compromises the benefits of minimally invasive surgery in endometrial cancer patients with a large uterus or utero-vaginal discrepancy.</p><p><strong>Methods: </strong>This is a retrospective multi-institutional study, including endometrial cancer patients with FIGO 2009 clinical stage I-II, undergoing minimally invasive staging surgery (laparoscopic or robot-assisted) followed by minilaparotomic specimen retrieval. A propensity-matched algorithm was used to compare outcomes of minimally invasive staging with open surgery.</p><p><strong>Results: </strong>The study included 45 propensity-matched pairs (90 patients): 45 underwent minimally invasive staging with minilaparotomic specimen retrieval and 45 underwent open staging. Patients undergoing minimally invasive surgery plus trans-abdominal specimen retrieval experienced longer median operative time (95 vs. 85 minutes; p=0.0017), lower blood loss (50 vs. 100 ml; p<0.001), and shorter length of hospital stay (3 vs. 5 days; p<0.001) in comparison to patients undergoing open surgery. No intraoperative complication occurred. No intraoperative transfusions were administered in both cohorts. No statistically significant differences in complications rates were registered between groups (p=0.266). No differences in term of disease-free (p=0.833, log-rank test) and overall (p=0.723, log-rank test) survival was noted between groups.</p><p><strong>Conclusions: </strong>Transabdominal specimen retrieval does not reduce the benefits of minimally invasive staging in endometrial cancer with large uteri or utero-vaginal disproportion. Uterine size is not a limitation for minimally invasive surgery. Further studies are needed to confirm these results and define the optimal approach.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"59-66"},"PeriodicalIF":3.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145490554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}